Clinical trials: Lung
Scleroderma, Systemic
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade…
- Trial name
- NCT00333437
- Testing
- Mycophenolate mofetil
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Covid19
Impact of Colchicine and Low-dose Naltrexone on COVID-19
The purpose of this study is to explore the impact of two medications-colchicine and low-dose naltrexone (LDN)-relative to standard of care (SOC) on COVID-19 disease progression to severe/critical illness and/or intubation in…
- Trial name
- COLTREXONE (NCT04756128)
- Testing
- Colchicine 0.6 mg, Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- HealthPartners Institute
Acute Respiratory Distress Syndrome
KL₄Surfactant Treatment in Patients With ARDS
Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
- Trial name
- NCT00215553
- Testing
- A.1 Lucinactant, B.3 SoC, A.2 Lucinactant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Windtree Therapeutics
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or…
- Trial name
- NCT05037929
- Testing
- Astegolimab
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 1,334 people
- Sponsor
- Genentech, Inc.
Pneumothorax
Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure
BS-1053 A Prospective Randomized Multi-Centered Safety and Efficacy Evaluation of the Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedures
- Trial name
- NCT00562302
- Testing
- Bio-Seal Plug
- Where
- 18 sites in United States
- Volunteers
- 339 people
- Sponsor
- Angiotech Pharmaceuticals
Respiratory Distress Syndrome, Newborn
Aerosolized Surfactant in Neonatal RDS
Respiratory distress syndrome (RDS), caused by surfactant deficiency, is the leading cause of mortality and morbidity in preterm infants.
- Trial name
- AS-02 (NCT02294630)
- Testing
- Surfactant
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Sood, Beena G., MD, MS
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
- Trial name
- NCT03026166
- Testing
- Ipilimumab, Nivolumab, Rovalpituzumab tesirine
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- AbbVie
Healthy Volunteer
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers.
- Trial name
- NCT02224053
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing
- Where
- 2 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cystic Fibrosis, Advanced Lung Disease
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
The purpose of this study is to evaluate the safety and tolerability of LUM/IVA combination therapy in subjects 12 years and older with CF and advanced lung disease and who are homozygous for the F508del CFTR mutation
- Trial name
- NCT02390219
- Testing
- Lumacaftor, Ivacaftor
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Lung Cancer
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00066222
- Testing
- Cisplatin, Etoposide, Radiation therapy
- Where
- 104 sites in United States
- Volunteers
- 72 people
- Sponsor
- Radiation Therapy Oncology Group
Fatigue, Self Efficacy
Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience
Among 13 core symptoms across 3,106 breast, colorectal, prostate, and lung cancer patients, persons with lung cancer were the most symptomatic, with moderate to severe fatigue being reported with the greatest prevalence.
- Conditions
- Fatigue, Self Efficacy, Quality of Life, Physical Activity
- Trial name
- NCT03724331
- Testing
- Light Physical Activity 1, Light Physical Activity 2, Support Education Activity
- Where
- United States
- Volunteers
- 235 people
- Sponsor
- University of Nebraska
Neoplasms
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.
- Trial name
- NCT00424775
- Testing
- MK0683, vorinostat
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster…
- Trial name
- NCT05875701
- Testing
- NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Novavax
Cystic Fibrosis
Rollover Study of VX-770 in Cystic Fibrosis Subjects
The primary objective of the study was to evaluate the safety of long-term VX-770 treatment in participants with cystic fibrosis (CF).
- Trial name
- NCT01117012
- Testing
- Ivacaftor
- Where
- 58 sites in United States, Australia and 6 more
- Volunteers
- 192 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Lung Cancer
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00234052
- Testing
- bevacizumab, carboplatin, pemetrexed
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Northwestern University
Advanced Cancer
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of…
- Trial name
- NCT00106626
- Testing
- vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
COVID-19 3rd Dose Vaccine in Transplant Patients
The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.
- Trial name
- NCT05047640
- Testing
- BNT162b2 vaccine, JNJ-78436735 Vaccine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Giselle Guerra
Asthma
A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
- Trial name
- NCT00783289
- Testing
- Benralizumab 25 mg, Benralizumab 100 mg, Benralizumab 200 mg
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- MedImmune LLC
Asthma
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp…
- Trial name
- NCT01576718
- Testing
- Fp MDPI, Flovent Diskus, albuterol/salbutamol
- Where
- 300 sites in United States, Australia and 17 more
- Volunteers
- 889 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of onalespib lactate when given together with erlotinib hydrochloride and to see how well they work in treating patients with EGFR-mutant non-small cell lung cancer…
- Trial name
- NCT02535338
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Onalespib Lactate
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.